ワクチン開発用試薬

Loaded Monoclonal Anti-SARS-CoV-2 Spike RBD Antibody, Mouse IgG1 (Cat. No. SPD-M305) on AMC Biosensor, can bind SARS-CoV-2 Spike RBD, His Tag (B.1.1.529/Omicron) (Cat. No. SPD-C522e) with an affinity constant of 9.07 nM as determined in BLI assay (ForteBio Octet Red96e).

Immobilized  SARS-CoV-2 Spike RBD (Omicron, Cat. No. SPD-C522e) can bind Anti-SARS-CoV-2 Spike RBD Antibody, Mouse IgG1(Cat. No.SPD-M305) with a linear range of 0.4-12.5 ng/mL. The antibody does not bind  Spike RBD of WT (Cat. No. SPD-C52H1), Alpha (Cat. No. SPD-C52Hn), Beta (Cat. No. SPD-C52Hp), Delta(Cat. No. SPD-C52Hh) and Gamma (Cat. No. SPD-C52Hr).

Competitive ELISA

Post-vaccination serum NAb test (Cat. No. RAS-N022) demonstrates high sensitivity and accuracy

16 convalescent serum samples were tested for neutralizing antibody level with pseudovirus and ELISA kit (Cat. No. RAS-N022), respectively. The results are highly correlated (R2 =93.73)。

56 post-vaccination (inactivated vaccines) serum samples are tested for neutralizing capacity against multiple strains (Alpha, Beta, Gamma, Delta) of SARS-CoV-2 with wild type (WT) and mutant-specific kits. Neutralization against all VOCs is lower than the WT, with Delta being the lowest.

Note：y = (A - D) / [1 + (x/C)^B] + D (A =1.55562 B =1.45522 C=14.42024 D=0.05532 r^2= 1)

SARS-CoV-2 Spike (WT) Fluc-GFP Pseudovirus (Cat. No. PSSW-HLGB001) and SARS-CoV-2 Spike (Omicron) Fluc-GFP Pseudovirus (Cat. No. PSSO-HLGB003) can be neutralized by Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody (Cat. No. SPD-M265, S1N-M122) with inhibition rates of more than 99%. The antibody, REGN10987, which has been reported that Omicron mutant strain can escape, can effectively neutralize SARS-CoV-2 Spike (WT) Fluc-GFP Pseudovirus (Cat. No. PSSW-HLGB001) but not SARS-CoV-2 Spike (Omicron) Fluc-GFP Pseudovirus (Cat. No. PSSO-HLGB003).

SARS-CoV-2 Spike (Omicron) Fluc-GFP Pseudovirus (Cat. No. PSSO-HLGB003) can be neutralized by serum from immunized mice. The inhibition rates come up to more than 99%.

SARS-CoV-2 Spike (WT) Fluc-GFP Pseudovirus (Cat. No. PSSW-HLGB001), SARS-CoV-2 Spike (Delta) Fluc-GFP Pseudovirus (Cat. No. PSSD-HLGB002) and SARS-CoV-2 Spike (Omicron) Fluc-GFP Pseudovirus (Cat. No. PSSO-HLGB003) can be neutralized by Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody (Cat. No. S1N-M122) with similar dose-effect relationship in various matrixes (culture medium with 0%, 2.5% or 5% human negative serum).

Anti-SARS-CoV-2 Spike RBD Neutralizing antibody (Cat. No.S1N-M122)neutralizes SARS-CoV-2 Spike RBD by inhibiting RBD: ACE2 interaction. The ACE2-coated plate is incubated with the wild type (WT) RBD or B.1.1.7, B.1.351, P.1, B.1.617.1, B.1.617.2 mutant and treated with the neutralizing antibody at increasing concentration. Percent inhibition is calculated based on the OD value.

As verified by SARS-CoV-2 spike pseudovirus neutralization test, the broad-spectrum neutralizing antibody (Cat. No. S1N-M122) can effectively neutralize wild-type and Alpha (B.1.1.7) /Beta (B.1.351) /Gamma (P.1) /Delta (B.1.617.2, data not shown) viral mutants, making it suitable as a quality control antibody in neutralizing antibody screening for mutant strains, neutralizing antibody detection in convalescent or vaccinated serum, etc.